Mayo Clinic Talks
Inflammation and Cardiometabolic Disease Edition: Hepatic Inflammation and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Podcast summary created with Snipd AI
Quick takeaways
- Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) includes various forms and necessitates screening for at-risk populations to prevent severe complications.
- The management of Metabolic Dysfunction Associated Steatohepatitis (MASH) focuses on lifestyle modifications and may involve new FDA-approved medications for advanced cases.
Deep dives
Understanding Metabolic Dysfunction Associated Steatotic Liver Disease
Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) represents a condition where fat accumulates in the liver due to underlying metabolic dysfunction. This umbrella term includes subcategories like Metabolic Dysfunction Associated Steatohepatitis (MASH), which is a more aggressive form of the disease, and MET-ALD, which refers to fatty liver in those who consume low to moderate amounts of alcohol. The primary risk factors related to MASLD involve insulin resistance, obesity, diabetes, dyslipidemia, and hypertension, with studies showing a significant prevalence of liver fat among diabetic patients. It is important that healthcare providers screen at-risk populations, as timely intervention can prevent progression to more severe liver disease.
Remember Everything You Learn from Podcasts
